My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 111

    1.

    The multichain interleukin-2 receptor: a target for immunotherapy.

    Waldmann TA, Pastan IH, Gansow OA, Junghans RP.

    Ann Intern Med. 1992 Jan 15;116(2):148-60. Review.PMID: 1727619 [PubMed - indexed for MEDLINE]Related articles

    2.

    Anti-IL-2 receptor monoclonal antibody (anti-Tac) treatment of T-cell lymphoma.

    Waldmann TA.

    Important Adv Oncol. 1994:131-41. Review.PMID: 8206486 [PubMed - indexed for MEDLINE]Related articles

    3.

    The interleukin-2 receptor: a target for immunotherapy.

    Waldmann TA, Goldman C, Top L, Grant A, Burton J, Bamford R, Roessler E, Horak I, Zaknoen S, Kasten-Sportes C, et al.

    Adv Exp Med Biol. 1992;323:57-66. Review. No abstract available. PMID: 1485565 [PubMed - indexed for MEDLINE]Related articles

    4.

    Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma.

    Waldmann TA.

    J Natl Cancer Inst. 1989 Jun 21;81(12):914-23. Review.PMID: 2659803 [PubMed - indexed for MEDLINE]Related articles

    5.

    Lymphokine receptor-directed therapy: a model of immune intervention.

    Waldmann TA, Grant A, Tendler C, Greenberg S, Goldman C, Bamford R, Junghans RP, Nelson D.

    J Clin Immunol. 1990 Nov;10(6 Suppl):19S-28S; discussion 28S-29S. Review.PMID: 2081786 [PubMed - indexed for MEDLINE]Related articles

    6.

    The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.

    Waldmann TA, Goldman CK.

    Am J Kidney Dis. 1989 Nov;14(5 Suppl 2):45-53. Review.PMID: 2683757 [PubMed - indexed for MEDLINE]Related articles

    7.

    1992 Stohlman Memorial Lecture: targeting the IL-2 receptor.

    Waldmann TA.

    Leukemia. 1993 Aug;7 Suppl 2:S151-6.PMID: 8361223 [PubMed - indexed for MEDLINE]Related articles

    8.

    Lymphokine receptor-directed therapy: a model for immune intervention in leukemia, autoimmunity, and immunodeficiency.

    Waldmann TA.

    Clin Immunol Immunopathol. 1991 Nov;61(2 Pt 2):S37-46. Review.PMID: 1934612 [PubMed - indexed for MEDLINE]Related articles

    9.

    The role of the multichain IL-2 receptor complex in the control of normal and malignant T-cell proliferation.

    Waldmann TA, Tsudo M.

    Prog Clin Biol Res. 1988;262:283-93.PMID: 2897696 [PubMed - indexed for MEDLINE]Related articles

    10.

    IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.

    Phillips KE, Herring B, Wilson LA, Rickford MS, Zhang M, Goldman CK, Tso JY, Waldmann TA.

    Cancer Res. 2000 Dec 15;60(24):6977-84.PMID: 11156399 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Lymphokine receptors: a target for immunotherapy of lymphomas.

    Waldmann TA.

    Ann Oncol. 1994;5 Suppl 1:13-7. Review.PMID: 8172810 [PubMed - indexed for MEDLINE]Related articles

    12.

    Targeting human IL-2 receptors for diagnosis and therapy.

    Nelson DL, Kurman CC.

    Proc Soc Exp Biol Med. 1994 Jul;206(3):309-11. Review.PMID: 8016170 [PubMed - indexed for MEDLINE]Related articles

    13.

    Recombinant single-chain immunotoxins against T and B cell leukemias.

    Kreitman RJ, Pastan I.

    Leuk Lymphoma. 1994 Mar;13(1-2):1-10. Review.PMID: 8025511 [PubMed - indexed for MEDLINE]Related articles

    14.

    Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.

    Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C.

    Cancer Res. 1990 Mar 1;50(5):1495-502.PMID: 2406013 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    IL-2 receptor expression in the haematologic malignancies: a target for immunotherapy.

    Waldmann TA.

    Cancer Surv. 1989;8(4):891-903. Review.PMID: 2701734 [PubMed - indexed for MEDLINE]Related articles

    16.

    The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of HTLV-I-associated disorders.

    Waldmann TA.

    J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S179-85. Review.PMID: 8797721 [PubMed - indexed for MEDLINE]Related articles

    17.

    The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.

    Kreitman RJ, Chaudhary VK, Waldmann T, Willingham MC, FitzGerald DJ, Pastan I.

    Proc Natl Acad Sci U S A. 1990 Nov;87(21):8291-5.PMID: 2236041 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.

    Kreitman RJ, Chang CN, Hudson DV, Queen C, Bailon P, Pastan I.

    Int J Cancer. 1994 Jun 15;57(6):856-64.PMID: 8206679 [PubMed - indexed for MEDLINE]Related articles

    19.

    The IL-2/IL-15 receptor systems: targets for immunotherapy.

    Waldmann TA.

    J Clin Immunol. 2002 Mar;22(2):51-6. Review.PMID: 11998892 [PubMed - indexed for MEDLINE]Related articles

    20.

    Targeting Pseudomonas exotoxin to hematologic malignancies.

    Kreitman RJ, Pastan I.

    Semin Cancer Biol. 1995 Oct;6(5):297-306. Review.PMID: 8562907 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity